eligible ages (years): 18.0-55.0,  All  Major Depressive Disorder For Patients with Major Depressive Disorder • Male and female outpatients, aged 18-55 years Subjects meeting full for the diagnosis of current Major Depressive Disorder (MDD) without psychotic features, as determined by clinical evaluation and Mood Module of structured diagnostic interview (SCID), completed by the study clinician HAM-D17 score of 14 or higher Able to provide informed consent Right handed, normal (corrected) vision and normal hearing  • Other primary diagnoses including major depressive disorder with psychotic features, bipolar disorder, schizoaffective disorder, schizophrenia, dementia, attention deficit hyperactivity disorder (ADHD) Substance use disorder (abuse or dependence with active use within the last 6 months) Significant sensory deficits such as deafness or blindness Severe or unstable medical illness, including history of closed head injury resulting in loss of consciousness, seizure disorder; history of neurological disorders Pregnant or nursing females who are not using an accepted method of contraception (birth control pill, IUD, combination of barrier methods) Clinically significant abnormal laboratory values or electrocardiogram For Healthy Controls Males and females, aged 18-55 years Subjects who do not meet full for any of the major psychiatric diagnosis including MDD, bipolar disorder, schizophrenia, substance abuse/dependence, attention deficit hyperactivity disorder (ADHD), as determined by clinical evaluation and structured diagnostic interview, completed by the study clinician Right handed, normal (corrected) vision and normal hearing Any current primary psychiatric, or medical condition determined to be clinically significant


A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

eligible ages (years): 18.0-999.0,  All  Depressive Disorder, Major Depressive Disorder, Minor Dysthymic Disorder Males and Females, ages 18 and older who are self-reporting generally good health Newly started on an antidepressant medication, switched to a different antidepressant medication or prescribed an increased dosage of antidepressant medication within the past 2 weeks A Hamilton Depression Rating Scale (HAM-D) score of greater than 10 A Patient Health Questionnaire (PHQ-9) score of 10 or greater, with endorsement of depressed mood or anhedonia, and endorsement of impaired daily function Meets diagnostic for Major Depressive Disorder, persistent Minor Depressive Disorder (i.e., > 1 month duration), or Dysthymic Disorder via a structured interview with the PRIME-MD Able to read, understand, and sign the Informed Consent in English Willing and able to comply with study requirements Well-versed in using a personal computer and the internet and must have easy access to a computer connected to the internet everyday (both weekdays and weekends) Enrollment in Surescripts Pharmacy benefit plan Currently under care with a Provider in Family Medicine at Cheshire Medical Center / Dartmouth-Hitchcock Keene  Subjects must not have a major psychiatric co-morbid condition (schizophrenia, bipolar affective disorder, obsessive-compulsive disorder, PTSD, or a depressive disorder with psychotic features, as determined from chart review and patient report) Subjects must not have a substance use disorder or dependence as assessed by: CAGE Alcohol Dependence Questionnaire score >3 Subjects must not have a history of treatment -resistant depression as defined by the following: Psychiatric hospitalization within the past year; More than 2 clinically ineffective antidepressant medication trials, of adequate duration and adequate dose, within the current depressive episode; Any history of Electroconvulsive Therapy (ECT); A trial of Monoamine Oxidase inhibitor (MAO) within the past year Subjects must not report being actively suicidal Subjects must score 4 or greater on the Callahan Six-Item Cognitive Screening assessment Subjects must not be diagnosed with a terminal or near terminal medical illness such that their primary care provider has estimated the patient has less than 6 months to live Subjects reporting any medical condition that would make it unsafe to participate in a research study Participation in any other clinical research study within the past 30 days Participation in any on-line depression-related coaching or lifestyle improvement program within the past 5 years


eligible ages (years): 18.0-24.0,  All  Depression Alcohol Abuse Currently enrolled in college as an undergraduate student Ages 18-24 years (inclusive) Presence of two binge drinking episodes in the past month (defined as consumption of 5 or more drinks in 2 hours for males and 4 for females; NIAAA, 2004) BDI-II 12 (12 is often used to indicate the presence of at least mild depressive symptoms) and <30 (indicating severe depression)  Meeting for substance dependence or abuse (any substance) in the past six months (students with alcohol abuse will not be excluded) Diagnosis of bulimia, psychosis, or bipolar disorder Having received any psychosocial treatment for depression or substance abuse in the past month Having received CBT for depression and/or alcohol use in the previous 6 months If receiving pharmacological treatment for depression or substance abuse, has not been on a stable dose for at least 4 weeks Discontinued an antidepressant medication less than 1 month ago Meeting for severe depression or posing a serious suicide or homicide risk


eligible ages (years): 21.0-65.0,  All  Daily Oral Pexacerfont for 28 Days (300 mg/Day Loading Dose for 7 Days, Followed Placebo Body Mass Index (BMI) > 22 kg/m(2) Score of 15 or higher on the Dietary Restraint Scale, with endorsement of the Restraint Scale item Do you give too much time and thought to food? Age 21 years (4a) For women of childbearing potential: must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of study drug, and agree to use an adequate method of contraception to avoid pregnancy for a period of 6 months beginning from first dose of randomized treatment. Women of childbearing potential any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. Adequate methods of contraception for sexually active women are having a male sexual partner(s) who is surgically sterilized prior to inclusion; having a sexual partner(s) who is/are exclusively female; using oral contraceptives (either combined or progesterone only) with a single-barrier method of contraception consisting of spermicide and condom or diaphragm; using double-barrier contraception, specifically, a condom plus spermicide and a female diaphragm or cervical cap; or using an approved intrauterine device (IUD) with established efficacy (4b) Men, unless surgically sterilized (vasectomy with documentation of azoospermia), must agree to practice abstinence or use barrier contraception, and not donate sperm, for a period of 6 months beginning from first dose of randomized treatment  Current employment at NIDA IRP or Bristol-Myers Squibb (BMS), or being in the immediate family of an employee. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted Current participation in another clinical study that includes exposure to an investigational or non-investigational drug or device Participation in a clinical study for a condition related to weight or dieting within the preceding month Any history of participation in a trial involving pexacerfont or closely related compounds Any medical condition or laboratory finding that, in the judgment of the investigators, could adversely affect safety or study integrity. Examples but are not limited to diabetes type 1 and type 2, ischemic heart disease, uncontrolled hypertension, and history of cerebrovascular accident or transient ischemic attack For women: pregnancy, breastfeeding, or planning to become pregnant within 6 months from the administration of first dose of study drug Past or present diagnosis of any eating disorder, including Anorexia Nervosa, Bulimia Nervosa, and Eating Disorder NOS (e.g., Binge-Eating Disorder). (Eating-disordered individuals probably represent a distinct population and should therefore be studied separately.) Past or present diagnosis of schizophrenia, bipolar disease, or any psychotic disorder; past or present diagnosis of dementia or any other disorder that has led to a clinically significant cognitive impairment; present diagnosis of any mood or anxiety disorder; any other psychiatric condition that presently requires, or in the past month has required, pharmacological intervention Past or present diagnosis of any substance-use disorder except nicotine dependence Urine tests positive for illegal drugs


eligible ages (years): 18.0-999.0,  All  Insomnia Major Depression Minor Depression Clinical level of Insomnia (more than 10 on ISI) Meets for Insomnia according to DSM-IV-TR Enough language skills Only Trial 1: Meets for Major or Minor Depressive Disorder according to DSM-IV-TR (for minor depression a MADRS-S-level of >19 is required)  Sleep disorders requiring other treatment Alcohol/drugs abuse Started to use or changed the dose of antidepressant drug during the last 2 months Somatic or psychiatric conditions requiring acute care Working night shifts Only Trial 2: Meets for Major or Minor Depressive Disorder according to DSM-IV-TR (for minor depression a MADRS-S-level of >19 is required for exclusion)


eligible ages (years): 18.0-65.0,  All  Acute Mountain Sickness Healthy adults  History of serious illness Current smoker or Hemoglobin >15.5gm/dL Uncontrolled hypertension


eligible ages (years): 18.0-999.0,  All  Major Depressive Disorder Metabolic Syndrome Thyroid Dysfunction patient with major depressive disorder age over 18 years  subject who cannot give information


eligible ages (years): 18.0-999.0,  All  Major Depressive Disorder Neoplasms Diagnosed with a malignancy Informed consent obtained and signed Greater than or equal to 18 years of age Life expectancy determined to be greater than or equal to 6 months Diagnosed with Major Depressive Disorder based on clinical examination and the DSM-IV-TR PHQ-9 depression assessment completed by subject, with a score of 10 or greater Able to take whole or crushed tablets by mouth or by feeding tube  Unable to complete self-report instruments due to illiteracy, neurologic illness, visual problems, inability to speak or read English, or other causes Treatment with antidepressants or antipsychotics within the last 3 months Psychotic or manic behavior Active suicidal ideation or plan Current illicit substance abuse Severe renal impairment as defined by creatinine clearance of <15 milliliters/minute/1.73 meters squared (mL/min/m2) Severe hepatic impairment as defined by Aspartate Aminotransferase (AST) or alanine aminotransferase (ALT) >5x the upper limit of normal, or a total bilirubin > 3.0 milliliters/deciliter (mL/dL) History of congenital long QT syndrome Clinically significant congestive heart failure or bradyarrhythmias Treatment with a concomitant medication that is known to have a strong association with corrected QT interval (QTc) prolongation AND a QTc >460 for men or >470 for women. Applicable to the citalopram arm only


eligible ages (years): 12.0-999.0,  All  Major Depressive Disorder Adult Cohort A. MDD Mothers Cohort Current or past Major Depressive Disorder English as first language or English fluency Biological daughter who meets inclusion/  for High Risk Female Adolescent B. Healthy Control Mothers Cohort No history of psychopathology English as first language or English fluency Biological daughter who meets inclusion/ for Healthy Female Adolescent Adolescent Cohort General for Adolescent Cohorts Female Ages 12-14


eligible ages (years): 18.0-65.0,  All  Depression All those who fulfil the diagnostic of Depressive episode (F32) or Recurrent depressive disorder (F33 except 33.4 ) using ICD10 RDC (based on interviews using SCAN Urdu version) Are between the ages of 19-60 Score 8 or more on HADS, Depression Subscale, and Who live within traveling distance of the psychiatry department will be approached  Excessive use of alcohol or drugs (using ICD 10 RDC for alcohol or drug abuse or dependence) Significant cognitive impairment (for example learning disability or dementia) and Active psychosis


eligible ages (years): 18.0-999.0,  All  College Student Mental Health for Counselors Currently working at a College Counseling Center Willingness to take the ACT guided self-help training through the counselor portal until reaching a passing criterion of 80% Willingness to distribute flyers about the study to five students, in an attempt to recruit 3 clients to participate in the self-help modules  for Counselors Prior participation in this study for Student Clients Currently being treated at a College Counseling Center Willingness to participate in three half-hour modules as part of a web-based guided self-help program and complete pre and post assessments across a period of 4 weeks Referred to the study/self-help modules by counselor Participation will comply with targeted enrollment plans, and attention will be paid to selecting an ethnically/racially diverse group Student is clinically stable as per counselor judgment (e.g., not actively suicidal, psychotic, or disruptive) for Student Clients Under 18


eligible ages (years): 15.0-19.0,  All  Depression Beck Depression Inventory > o = 10 Meets diagnostic of a depressive disorder according Kiddie Sads Present and Lifetime Version interview (K-SADS-PL) Parent or caregiver giving informed consent and adolescent giving informed assent  Suicidal risk requiring in-patient care Bipolar Disorder Current substance dependence Current alcohol dependence Current psychosis Low intellectual abilities Current treatment with antidepressant and/or psychotherapy


eligible ages (years): 18.0-999.0,  All  Treatment Resistant Depression Primary diagnose of unipolar treatment resistant depression  Patients diagnose of: bipolar disorder, psychosis, high suicide risk, Intellectual disability, illicit drug dependence Currently in or having received psychotherapy in the last 4 weeks


eligible ages (years): 12.0-17.0,  All  Depression Currently in the 6th to 11th grades Adolescent and parent must be English-speaking Parental consent and adolescent consent  Presence of current Major Depressive Disorder, dysthymia, bipolar disorder, or significant psychosis Suicide attempt in the past week or significant suicidal ideation in the past week Presence of significant psychopathology or significant pervasive developmental delays that would make the group inappropriate


eligible ages (years): 18.0-999.0,  All  Depression Anxiety Suicidal Ideation Eating Disorders Student enrolled in a participating campus as a full-time, residential undergraduate during the 2009-2010 or 2010-2011 academic years. Student must have been living in a participating residence hall  Students under 18 years of age


eligible ages (years): 18.0-55.0,  All  Depressive Disorder, Major Age between 18-55, male or female The diagnosis of MDD consistent with DSM-IV (M.I.N.I) First-episode or relapsed Certain ability of reading and writing to complete the questionnaire survey and psychological assessment All participants provide written confirmation of informed consent prior to engaging the study protocol  Current psychopathology or a history of neurologic conditions, including alcohol/substances dependence, the diagnosis of cognition impairment Severe somatic diseases, such as severe cardio-cerebral vascular diseases, respiratory diseases, liver diseases, kidney diseases, or malignant tumors Not signed the informed consent Been engaging other studies


eligible ages (years): 18.0-999.0,  All  Dementia English speaking Have a family member or friend with dementia who resides in Long Term Care  persons who are non-autonomous adults cognitively impaired as determined by the Registered Nurse (RN) researcher unable to participate, in the opinion of the RN researcher non-English speaking does not have a family member or friend with dementia in Long Term Care


eligible ages (years): 18.0-80.0,  All  Multiple Sclerosis Definite diagnosis of MS (14,15) or CIS (16);according to the most recent standard Expanded Disability Status Scale (EDSS) score < 7.0 (17) Last magnetic resonance imaging (MRI) within the previous 12 months Male or female >18 years old Willing to perform the study procedures Signed Informed consent  Mini Mental Status Examination (MMSE) score < 24 Relapse within the last 3 months Radiologically isolated syndrome (RIS) History of drug and/or alcohol abuse Any serious general medical condition like decompensated cardiopulmonary disease, cancer or decompensated renal failure, as well as any neurological condition (other than MS) that can interfere with the correct execution of the study design


eligible ages (years): 18.0-999.0,  All  Depression Anxiety Fatigue Sleepiness Sleep Disruption Being a first year medical student Good academic standing after the first module Reporting attending morning lectures regularly  No reported history of psychiatric illness,sleep illness, ophthalmic illness No current use of photosensitizing medications


eligible ages (years): 18.0-80.0,  All  Healthy Young and Older Adults right handedness unobtrusive neuropsychological screening ability to provide written informed consent no pathological findings in head MRI age: 18 to 35 years (young adults) or 50-80 years (older adults) Highly effective contraception (Pearl Index < 1) or reliable abstinence from any heterosexual relationships in women of childbearing potential  severe internal or psychiatric disease (especially depression or suicidal thoughts) epilepsy cognitive impairment (< SD under age adjusted norm in neuropsychological testing) concurrent taking of serotonin precursors (tryptophan, 5-HTP) or MAO inhibitors concurrent taking of tramadol or triptans concurrent taking of pimozide or linezolid concurrent taking of other drugs prolonging the QT-interval long-QT-syndrome hypokalemia or hypomagnesemia known intolerance of the study medication


eligible ages (years): 12.0-18.0,  All  Adolescent - Emotional Problem Depression Prevention Harmful Effects enrolled in one of the participating schools parental consent and student assent is required for the web-based survey  not enrolled in the participating schools


eligible ages (years): 18.0-999.0,  All  Marital Relationships Family Relations Low-Income Population Child Behavior Adolescent Behavior To be eligible for the study, couples were supposed to be low income, married, at least 18 years old, and either expecting a child or parents of a child under age 18 who was living in their home - though couples were not required to provide any documentation verifying that they met these criteria They also had to understand one of the languages in which SHM services were offered (English or, in some locations, Spanish)  Indication of domestic violence in the relationship


eligible ages (years): 18.0-65.0,  All  Depressive Disorder, Major Moderate to severe major depressive disorder  Prior treatment with botulinum toxin of any serotype for any reason Use of antidepressant medication for depression within 2 weeks of study Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis


eligible ages (years): 18.0-999.0,  All  Depression Anxiety Alcohol Abuse Tobacco Abuse English-speaking US residents ages 18 and older below 50% of the area median income have a regular Internet connection  non-English speakers non-US residents children history of or current enrollment in other incentivized savings programs


eligible ages (years): 18.0-24.0,  All  Physical Activity be currently enrolled in full-time university coursework be between 18 and 24 years old understand and respond to screening questions in English be able to read at a Grade 6 level have adequate health, as assessed by having a body mass index between 18.5 and 29.9 (anyone with a BMI of 30+ is considered obese; National Heart, Lung, & Blood Institute, 2012) to ensure that regular, moderate to intense exercise activity will not negatively affect health identify as individuals who have tried to initiate and continue an exercise regimen sometime in the past but have been unable to maintain the activity indicate the desire to initiate physical activity at the current time be willing to attempt to maintain an exercise schedule during the three-week intervention period to which they will be randomly assigned be willing to participate in the 2-month and 6-month follow up periods  not already be meeting current physical activity recommendations (i.e., at least 150 minutes of moderate-intensity exercise per week) not have major cognitive impairments (i.e., assessed by whether they can understand and respond adequately to all screening questions) not report consuming more than three (women) or four (men) alcoholic drinks per day (as this may interfere with their ability to engage in physical activity and confound study results) not be pregnant not have children not have preexisting physical limitations or recent injuries not have major cognitive impairments (i.e., assessed by whether they can understand and respond adequately to all screening questions)


eligible ages (years): 18.0-999.0,  All  Depression Participant ≥ 18 years Participant meets for a DSM-V Major Depressive episode. are as follows: Five or more symptoms present during the same 2-week period, including either 1 or 2: 1) depressed mood, 2) loss of interest or pleasure, 3) significant weight loss or gain, 4) insomnia or hypersomnia, 5) psychomotor agitation or retardation, 6) fatigue or loss of energy, 7) feelings of worthlessness or excessive or inappropriate guilt, 8) diminished ability to think concentrate or make decisions, and 9) recurrent thoughts of death, recurrent suicidal ideation, suicide attempt or plan MADRS score of 20 or more  DSM-V psychotic disorder Drug or alcohol abuse or dependence (preceding 6 months) Inadequate response to ECT (current episode of depression) Regular benzodiazepine medication Rapid clinical response required, e.g., due to high suicide risk Clinically defined neurological disorder or insult Metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites Pregnancy


eligible ages (years): 45.0-60.0,  All  Cardiovascular Diseases Diabetes Dyslipidemias Metabolic Syndrome Quality of Life Age: 45-60 years Not to have other severe somatic or psychiatric disorders, or other diseases that prevent physical loading (Answer "no" to all questions on the Physical Activity Readiness Questionnaire-PAR-Q)  Not to be engaged in regular physical activity >20 min on >3 days/week Able to ambulate, with or without assistance Able to communicate Informed consent: Must be capable and willing to provide consent  Acute or terminal illness Myocardial infarction in the past 3 months Not capable to ambulate Unstable cardiovascular disease or other medical condition Upper or lower extremity fracture in the past 3 months Severe dementia (MMSE < 10) Unwillingness to either complete the study requirements or to be randomised into control or training group Presence of neuromuscular disease or drugs affecting neuromuscular function


eligible ages (years): 18.0-999.0,  All  Schizophrenia Major Depressive Disorder Bipolar Depressive Disorder Parkinson's Disease With Hallucinations at least 18 years-old have a diagnosis of schizophrenia, major depressive disorder, bipolar depressive disorder, parkinson's disease with hallucination such patients should receive antipsychotics as their usual treatment they should give informed consent before participating  no treatment with atypical antypsichotics other diseases


eligible ages (years): 18.0-999.0,  All  Depressive Disorder, Major Being 18 years of age or older • Meet DSM-IV diagnostic for MDD confirmed by MINI International Neuropsychiatric Interview version 5.0 Informed Consent • Having access to a PC and Internet connection • Having a Smartphone that is compatible with the mobile component of the intervention • Understanding of the German language spoken and written  • Current high risk for suicide according to the MINI Interview section C • Serious psychiatric co-morbidity: substance dependence, bipolar affective disorder, psychotic illness, obsessive compulsive disorder, as established at the MINI interview • Currently receiving psychological treatment for depression • Being unable to comprehend the spoken and written language (German) • Not having access to a PC and fast Internet connection (i.e. broadband or comparable) • Not having a Smartphone that is compatible with the mobile component of the intervention that is offered or not willing to carry a Smartphone during the duration of treatment


eligible ages (years): 20.0-65.0,  All  Major Depressive Disorder For MDD subjects Subject meets the DSM-IV for MDD Subject has a minimum score of 18 on the 17-item HAMD total score Subject has a minimum score of 2 on item 1, depressed mood, of HAMD Subject is free from prior antidepressant medication for at least 5 times of elimination half-lives For healthy subjects Subject without past or current neuropsychiatric illnesses based on a clinical interview including Mini-International Neuropsychiatric Interview (M.I.N.I.) and a physical examination Subject without exposure to psychotropic medication or other substances known to affect the brain serotonin system within 1 year prior to entering the study  Subject with history of any co-morbid neuropsychiatric disease Subject with history of treatment resistant to at least two full doses and courses of antidepressant medication Subject with history of alcohol or substance dependence or abuse Subject with allergic history to the investigational products Subject with severe cardiovascular disease or cerebrovascular disease which is judged by investigators for safety concerns as inappropriate for this study Subject with malignancy within past 5 years Subject with any diseases judged by investigators as inappropriate for this study Female subject being pregnant, nursing, or lactating Female subject of childbearing potential not using a medically acceptable form of birth control Subject is unable to undergo MRI scan to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations


eligible ages (years): 18.0-65.0,  All  Depression Depressive Disorder patients referred to the recruitment sites for treatment for depression mild, moderate or severe depression mild, moderate or severe episode of recurrent depression  bipolar or psychotic depression psychotic disorder severe substance abuse disabilities in senses that affect functioning and severely threat completing the trial diseases that affect vitamin D metabolism (such as sarcoidosis, hypercalcemia, hypofunction of kidney) pregnancy or lactation current use of high dose vitamin D supplementation current use of high dose calcium supplementation


eligible ages (years): 18.0-999.0,  All  Major Depressive Disorder Bipolar, Depression We will recruit up to 80 participants who are adults (≥18yrs) have a confirmed psychiatric assessment of Major Depressive Disorder (MDD) and/or Bipolar II, depressive are of moderate or higher severity (PHQ-9 >14) are community-dwelling and able to attend Group Medical Visits in the Lower Mainland are able to comply with scheduled visits, treatment plan, and other procedures read, write, and speak English with acceptable auditory and visual acuity provide signed/dated informed consent; and able to walk independently  Active psychotic symptoms a primary active diagnosis of substance abuse Participants will need to have a working proficiency in English as group discussions, accompanying texts, and instructions will all be in English. To provide adequate translation services for these elements in one or more other languages is beyond our budget and may also influence the dynamics of the GMV. It could be considered in a future iteration of this research program


eligible ages (years): 18.0-65.0,  All  Major Depressive Disorder Bipolar I Disorder Bipolar II Disorder Bipolar Depression Suicidal Ideation Provision of written informed consent [MDD stream only] Diagnosis of major depressive disorder, currently depressed as determined by DSM-IV diagnostic (confirmed using the MINI) [BD stream only] Diagnosis of bipolar disorder, type I or type II, currently depressed as determined by DSM-IV diagnostic (confirmed using the MINI) Both females and males, aged 18 to 65 years Inpatient status Female patients of childbearing potential must have a negative urine human chorionic gonadotropin (hCG) test at enrolment and must be taking or willing to take some acceptable form of birth control during the course of the study if they are or plan to be sexually active The ability to understand and comply with the requirements of the study and capable of providing informed consent Suffering from suicidal ideation/attempts as evidenced by a score of >0 on either of the SSI or CSSRS or both  Current or past psychotic symptoms Substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV within 4 weeks prior to enrollment Any pervasive developmental disorder (according to DSM-IV criteria) Diagnosis of dementia (according to DSM-IV criteria) Known intolerance or hypersensitivity to ketamine or midazolam as judged by the investigator Significant medical condition that would contraindicate the use of ketamine, midazolam or that is untreated and would need urgent attention (as determined by treating physician) Medical conditions that would significantly affect absorption, distribution, metabolism, or excretion of ketamine or midazolam Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator Any clinically significant deviation from the reference range in clinical laboratory test results as judged by the investigator


eligible ages (years): 18.0-999.0,  All  Depression Anxiety Stress Participants must be at least 18 years of age. Participants must have self-reported mild to severe symptoms of depression (5-27+) according to PHQ-9, self-reported mild to severe symptoms of anxiety (5-21+) according to GAD-7, or self-reported mild to severe symptoms of stress (15-34+) according to the stress sub-scale of DASS-21  Students who currently are in face-to-face therapy at UCCS or BHS will be excluded. Students who score in the "red zone" in terms of risk of self-harm on the screening questions routinely used at UCCS will not be referred to the study. Students who score greater than 0 on the PHQ-9 self-harm item during the initial screening phase will be automatically directed to be further evaluated and alerted that a counselor will try to reach them. Based on this further evaluation, they may be recommended to seek help from their health/counseling service and may/may not be eligible to participate in the study. They will be telephoned within 1 working day and contacted by email if they cannot be reached by phone


eligible ages (years): 20.0-65.0,  All  Major Depression unipolar major depressive disorder  neurological diseases or relevant psychiatric diseases other than major depressive disorder current medication other than SSRI or Mirtazapine manic episodes (lifetime) psychotic symptoms (lifetime) treatment with psychotherapy within the past 2 years treatment with electroconvulsive therapy (lifetime)


A 10 yo boy with nighttime snoring, pauses in breathing, and restlessness with nighttime awakenings. No history of headache or night terrors. The boy's teacher recently contacted his parents because she was concerned about his declining grades, lack of attention, and excessive sleepiness during class.

eligible ages (years): 0.0-999.0,  All  Lung Diseases Sleep Apnea Syndromes


eligible ages (years): 1.0-18.0,  All  Obstructive Sleep Apnea Syndrome Cleft Lip/Palate children with cleft lip/palate and signs and symptoms of OSAS, parents who can read and write English  Parents who cannot read and write English, children with severe neurological compromise


eligible ages (years): 5.0-10.0,  All  Attention Disorder With Hyperactivity (ADHD) We will compare a group of children with ADHD, other psychiatric disorder, and a healthy group of children age 5  mental retardation -


eligible ages (years): 3.0-12.0,  All  Sleep Sleep Apnea Syndromes Sleep Disordered Breathing Assent of child (if over the age of 9 or younger but able to understand the nature of the study) At least one parent or guardian must sign an informed consent Child must be either a healthy volunteer or scheduled for an adenotonsillectomy for any reason Children scheduled for adenotonsillectomies must be referred to the program by a treating otolaryngologist who practices at the University of Michigan or St. Joseph Mercy Hospital in Ann Arbor, Michigan  Mental or physical limitations that would prevent proper interpretation of neurobehavioral tests Medical history that could confound interpretation of EEG or behavioral data, including epilepsy, psychiatric diagnoses (other than disruptive behavior disorders), head trauma with loss of consciousness for more than 30 seconds, or chronic medication use (e.g., benzodiazepines, other hypnotics, or antihistamines) Current treatment by a physician or past surgical treatment for SDB A known medical condition that carries independent high risk of SDB (e.g., Pierre Robin syndrome, Down syndrome, or neuromuscular disorders) or excessive daytime sleepiness (e.g., narcolepsy) Inability to schedule polysomnography, a Multiple Sleep Latency Test, and neurobehavioral testing before the surgical date Determination by any of the patient's physicians that sleep testing is required before surgery can be scheduled (to avoid the possibility that study enrollment itself could affect ability to complete the study) Prior enrollment of a sibling in the study Expectation that the child will no longer have convenient access to University of Michigan facilities within 6 months or expectation of further surgery within that period Additional for healthy volunteers


eligible ages (years): 20.0-80.0,  All  Obstructive Sleep Apnea Age 20 to 80 yrs Apnea hypopnea index (AHI) > 10/hr on Polysomnograph (PSG) with symptoms of obstructive sleep apnea (OSA) as described previously Epworth Sleepiness Scale (ESS) >10 Patients with hypertension will still be eligible to enter and continue the study as long as there is no alteration of anti-hypertensive medications during the study period  Patients having problems staying awake during driving, shift work Recent myocardial infarction Unstable angina Underlying malignancy


eligible ages (years): 18.0-999.0,  All  Seasonal Allergic Rhinitis Must be >=18 years of age and older, of either sex, and of any race Clinically symptomatic at Screening (Day -7 to -4)and at Baseline (Day 1) At Screening Visit, must have complaints of sleep disturbance while symptomatic with seasonal allergic rhinitis (SAR) and must have a score of 30 or greater for the Sleep Disturbance Sleep Scale (items 1,3,7 and 8) At the Baseline Visit, must have complaints of sleep disturbance and daytime somnolence while symptomatic with SAR and with a score of 30 or greater for the Sleep Problems Index II (SLP9) and 30 or greater for the Daytime Somnolence Sleep Scale (items 6, 9, and 11) Must have a 2-year or longer history of SAR occurring during the same season as the current study Must have skin tests positive for outdoor allergens common in subjects with SAR prevalent during the time of this study, such as, trees, grasses, weeds, ragweed, and molds. The skin tests should be performed at Screening if not done within 12 months prior to the Screening Visit Must be free of clinically significant disease that would interfere with study evaluations Women of childbearing potential need to use a medically accepted method of birth control prior to Screening and during the study, or provide documentation of surgical sterilization. Women who are not sexually active at enrollment must consent to the use of a medically accepted method of birth control if/when they become sexually active during study participation Female subjects of childbearing potential must have a negative urine pregnancy test at the time of enrollment at the Baseline Visit  Women who are pregnant, intend to become pregnant during the study, or are nursing Evidence of nasal polyps, deviated septum, or other intranasal anatomical obstruction(s) that would interfere with nasal airflow Acute or chronic sinusitis being treated with antibiotics and/or topical or oral nasal decongestants Acute respiratory infection within 2 weeks of the Screening Visit Diagnosis of clinically relevant sleep problems unassociated with allergies Complaints (within 12 months of the Screening Visit to their health-care provider) of difficulty sleeping or daytime sleepiness while not experiencing SAR symptoms, and continue with these complaints Snoring associated with an enlarged uvula or other upper airway pathology Had episodes of snoring associated with gasping or choking Awakened suddenly, on more than 1 occasion during the month preceding the Screening Visit, with a gasping or choking feeling Requires the use of oral appliances at night for bruxism (teeth gnashing) or temporomandibular joint problems


eligible ages (years): 18.0-999.0,  All  Sleep Apnea, Obstructive Experiences symptoms of OSA, including snoring and sleepiness Stable medical history with no change in medications that could affect sleepiness  Suspected diagnosis of a sleep disorder other than OSA (i.e., periodic leg movements, narcolepsy, insomnia, central sleep apnea, sleep hypoventilation syndrome) Medically unstable health conditions (e.g., heart attack, congestive heart failure) Use of psychotropic medications that cause sedation in the 3 months prior to study entry Recent or confirmed history of recreational drug use or alcohol abuse Pregnant Inability to communicate verbally, write, or read Visual, hearing, or cognitive impairment


eligible ages (years): 45.0-85.0,  All  Parkinson's Disease 85 years of age and living in the community Male or female of non-child bearing potentials (non-child bearing is defined as at lease 6 months post-menopause or surgically sterile) Must have a diagnosis of Parkinson's disease Must have complaints of sleep disturbance  Patients with diagnosis of or those meeting DSM-IV for major depression, schizophrenia or schizoaffective disorder, bipolar disorder, substance abuse disorder, other mental illness that is known to contribute to sleep disturbance, epilepsy, other medical conditions that are known to cause or contribute to sleep disturbances Patients currently using melatonin or ramelteon, hypnotics, benzodiazepines, antidepressants, blood-brain barrier permeable beta blockers, steroids, antipsychotics Patients with clinically significant blood or urine abnormalities Patients who have taken any investigational drug less than 1 month prior to the baseline visit Patients with multiple concomitant disorders with or without medications thought to produce sleep disturbances Patients with pre-existing sleep disturbances unrelated to Parkinson's disease Patients with severe hepatic impairment (Child-Pugh Class C) Patients with severe COPD (those with elevated pCO2 levels or those needing nocturnal oxygen therapy Patients with severe sleep apnea Patients who have sensitivity to ramelteon or any constituents of the Rozerem preparation


eligible ages (years): 2.0-18.0,  All  Insomnia Sleep Disorder Male or female between the ages of 2 years and 18 years Written consent must be obtained form the parent/legal guardian for all minors. Written assent must be obtained from all minors > 6 years of age Female subjects of child-bearing potential must not be pregnant and if females are fertile and sexually active, must have documented a negative urine HCG and assure use of effective contraception acceptable to the investigator (abstinence accepted) during the study period Subjects must meet the following for a diagnosis of insomnia as determined by the subject's private physician or study investigator and subject's history the complaint is significant difficulty (defined by frequency, severity, and/or chronicity) initiating or maintaining sleep;. The problem is viewed problematic by the child and/or caregiver the sleep disturbance causes clinically significant impairment in school performance, behavior, learning, or development for the child as reported by the child and/or caregiver the sleep disturbance does not occur exclusively in the context of an intrinsic dyssomnia such as narcolepsy, restless legs syndrome, or sleep-related breathing disorders; a circadian rhythm disorder; or a parasomnia the sleep disturbance is not attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication  Pregnancy and/or breastfeeding The presence of any untreated (where treatment is available), or unstable, progressive, or evolving clinically significant renal, endocrine, hepatic, respiratory, cardiovascular, neurologic, hematologic, immunologic, cerebrovascular disease or malignancy Elevations in screening blood tests of renal (SCr) and liver (ALT, AST and/or bilirubin) > 2 times the upper limit of normal for age Receiving any medications that may modulate Zolpidem metabolism, primarily drugs that will enhance or reduce the activity of CYP450 3A, 2C9, or 2D6 activity. Note: If patient is receiving a medication that might be considered an inducer or an inhibitor, please discuss with the PI prior to excluding them Receiving any medications with sleep-impairing properties at a dose/dose interval that would be judged by the study investigator as to interfere with the assessment of Zolpidem sleep response Currently using any systemic contraceptive steroids including: oral contraceptives, transdermal patch, vaginal insert, levonorgestrel implant and medroxyprogesterone acetate contraceptive injection


eligible ages (years): 30.0-80.0,  All  Sleep Apnea, Obstructive Continuous Positive Airway Pressure OSA confirmed by polysomnography (PSG) CPAP is the prescribed form of treatment for OSA Judged by sleep physician to respond to CPAP  Apnea/hypoxia index (AHI) less than 15 and no daytime functional symptoms or associated cardiovascular disease Diagnosis of another sleep disorder that causes arousals from sleep Past treatment for OSA Current substance abuse problem Diagnosis of a serious medical condition that would interfere with involvement in the study History of a major psychiatric disorder, other than depression Change in antidepressant medication in the 3 months before study entry


eligible ages (years): 4.0-9.0,  All  Sleep Problems Diagnosis of ASD Age greater than or equal to 4 or less than or equal to 9 years Current sleep problems, as defined as a composite score of greater than 41 on the CSHQ Failed sleep hygiene, as described below Parents must be fluent in English in order to complete CSHQ and ABC, validated in English only Parents have given informed consent  Current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.) Current or use within the last month of beta-blockers or melatonin Current use of sleep aids Presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease (GERD)) 5) Blindness


eligible ages (years): 18.0-65.0,  All  Schizophrenia Key The patient has a diagnosis of schizophrenia according to the DSM-IV-TR and the patient has been clinically stable in a nonacute phase of their illness Documentation that the patient has received treatment with olanzapine, oral risperidone, or paliperidone for schizophrenia for at least 6 weeks prior to the screening visit and has been on a stable dose of that antipsychotic medication for at least 4 weeks prior to the screening visit The patient is in good health (except for the diagnosis of schizophrenia) as judged by the investigator Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception barrier method with spermicide, intrauterine device (IUD), steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method, or documented abstinence The patient has a PANSS negative symptom score of 15 or more at the screening and baseline visits Key  The patient has a severity rating of moderate or worse on any item of the PANSS positive symptom subscale The patient has any Axis I disorder according to DSM-IV-TR including schizoaffective disorder, apart from schizophrenia and nicotine dependence, or any Axis II disorder that would interfere with the conduct of the study The patient has moderate to severe depressive symptoms, as indicated by the CDSS The patient has current active suicidal ideation, is at imminent risk of self-harm, or has a history of significant suicidal ideation or suicide attempt at any time in the past that causes concern at present The patient has tardive dyskinesia, akathisia, moderate or worse level of extrapyramidal symptoms, or any other clinically significant movement disorder The patient has a history of any cutaneous drug reaction or drug hypersensitivity reaction, a history of any clinically significant hypersensitivity reaction, or has a history of multiple clinically relevant allergies The patient is a pregnant or lactating woman The patient has previously received modafinil or armodafinil, or the patient has a known sensitivity to any ingredients in the study drug tablets


eligible ages (years): 9.0-14.0,  All  Sleep Difficulties in Pediatric Anxiety Disorder Generalized Anxiety Disorder Separation Anxiety Disorder Social Phobia Clinical diagnosis of DSM-IV diagnosis of Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), and Social Phobia (SP) Previous enrollment Cognitive Behavioral Therapy arm in ClinicalTrials.gov Identifier: NCT00774150 study, entitled, " Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study (CATS)" The child/adolescent must have a "sleep problem" defined as: difficulties at least 3 times within a 2-week period in one or more of the following domains difficulties going to sleep difficulties waking during the night difficulties getting up on time for school because of tiredness/sleepiness daytime tiredness and/or irritability that the child or parent attributed to insufficient sleep erratic sleep-wake schedules  IQ below 70 as assessed by the Wechsler Abbreviated Scale of Intelligence (WASI) Requires current ongoing treatment with psychoactive medications including anxiolytics and antidepressants Acutely suicidal or at risk for harm to self or others Any motor impairments or eye-hand coordination problems Sleep disorder or parasomnia Taking any medication that might interfere with sleep Has a medical problem that might interfere with sleep


eligible ages (years): 21.0-999.0,  All  Obstructive Sleep Apnea Consenting adults over the age of 21 Diagnosed obstructive sleep apnea  Unstable cardiovascular disease Uncontrolled hypertension (BP > 190/110) Severe intrinsic lung diseases (supplemental O2 > 2 L/min during the day) History of chronic renal insufficiency History of hepatic insufficiency Pregnancy Bleeding disorders or Coumadin use Sleep Disorders other than OSA Tracheostomy Allergy to lidocaine


eligible ages (years): 21.0-999.0,  All  Obstructive Sleep Apnea years or older Patient of the Weill Cornell Pulmonary Associates and Cornell Center for Sleep Medicine practices Clinically indicated for an overnight sleep study within six months prior to or after the outpatient office visit  Pregnancy


eligible ages (years): 18.0-65.0,  All  Resistant Hypertension Obstructive Sleep Apnea Age 18 known hypertension on ≧ 3 anti-hypertensive drugs Apnea-hypopnea index ≧15 able to give informed written consent  moderate renal impairment (glomerular filtration rate <30 mL/min/m2 ) endocrine/renal/cardiac causes of secondary HT congestive heart failure and clinically fluid overloaded On drugs that elevates BP e.g. NSAID, steroid Non-compliance to anti-hypertensive medications Unstable medical conditions such as unstable angina, recent myocardial infarction/stroke within 3 months Active inflammatory/infective conditions e.g. rheumatoid arthritis Excessive sleepiness that can be risky e.g. occupational driver, machine operator Modification/changes of anti-hypertensive regimen within 8 weeks


eligible ages (years): 4.0-10.0,  All  Autistic Disorder Insomnia Children with autism ages 4-10 years Diagnosis of autism based on Autism Diagnostic Observation Schedule (ADOS) Time to fall asleep of 30 minutes or longer by parent report at least 3 nights/week in the last 3 months Children may take seasonal allergy medications Children may take the following medications for the same dose at least 3 months: Citalopram (Celexa), Escitalopram (Lexapro), Amphetamine-dextroamphetamine (Adderall), Atomoxetine (Strattera), Methylphenidate(Ritalin), Dextroamphetamine(Dexedrine), Risperidone (Risperdal  Children taking medications other than those in the criteria Children with primary sleep disorder other than insomnia (such as sleep-disordered breathing) Children with non-febrile unprovoked epileptic seizure within the last two years Children with liver disease or high fat diets, as melatonin metabolism may be affected in these children Children who are visually impaired (partially or completely blind) as light suppresses melatonin synthesis and these children may have altered diurnal melatonin rhythms Children with known genetic syndromes co-morbid with autism including fragile X, Down syndrome, neurofibromatosis, or tuberous sclerosis Children who have outside normal limits on blood work for complete blood count, liver and renal function and hormone levels of ACTH, cortisol, LH, FSH, prolactin, testosterone and estradiol Tanner staging beyond level 1 at any time point in the study Children whose assessment score does not place them on the autism spectrum


eligible ages (years): 8.0-18.0,  All  Brain Tumors Age ≥8 to ≤ 18 years of age Brain tumor survivor ≥5 years post diagnosis ≥2 years post active cancer-directed therapy or observation only Parents speak and read English fluently Potential participant reads English fluently Potential participant/guardian willing to sign consent  Survivor of any cancer other than a brain tumor


eligible ages (years): 18.0-999.0,  All  Sleep Apnea Adults more than 18 years old  Subjects Unwilling to Complete the Questionnaire


eligible ages (years): 5.0-7.25,  All  Sleep Healthy child age 5-6 years old School enrollment for a minimum of 5 hours/day Positive Children's Sleep Habits Questionnaire (score ≥ 41) Permanent housing for the previous 12 months Permission for research staff to complete 5-9 home over 1 year Have telephone access or a contact with telephone access Fluent in either English or Spanish  Serious co-morbid condition that may impact sleep including genetic syndromes neuromuscular disorders seizure disorder mental retardation autism severe learning disabilities psychiatric disorders attention-deficit/hyperactivity disorder


eligible ages (years): 18.0-999.0,  All  Sleep Apnea, Obstructive diagnosis of obstructive sleep apnea syndrome  other causes of dysphagia pharyngeal surgery prior treatment for obstructive sleep apnea


eligible ages (years): 18.0-80.0,  All  Obstructive Sleep Apnoea Hypopnoea Syndrome Biomarkers of Fibrin Clot Structure Biomarkers of Vascular Endothelial Injury 80 year old with h/o daytime sleepiness, snoring and apnoeas  Refusal to give written informed consent Personal or family history of pro thrombotic or bleeding disorders, severe liver disease (clotting problems) and those prescribed warfarin or heparin Those with borderline sleep studies (4% Diprate or AHI 10-14 per hour) Aged less than 18 years or greater than 80 years


eligible ages (years): 5.0-12.0,  All  Sleep Apnea, Obstructive Sleep Apnea Syndromes Child Behavior Disorders Attention Deficit Disorder With Hyperactivity Disorders of Excessive Somnolence Children ages 5-12 years old Scheduled for an adenotonsillectomy for treatment of sleep apnea Child must provide assent, and Parent or legal guardian must be able to speak and read English, and agree to the study  No siblings of children already enrolled in the study Children who expect to have another surgery (in addition to AT) during the period of participation in this study Neurological, psychiatric, or medical conditions, or social factors that may affect test results, prevent children from returning for required study visits, or interfere with the study treatment, or Certain medications that affect sleepiness or alertness, for example Stimulants (such as Ritalin, Adderall, or Concerta) Sleep aides (such as Melatonin, Ambien, or Ativan), or Sedating medicines (such as Benadryl, Klonopin, Xanax, or Valerian)


eligible ages (years): 40.0-52.0,  All  Menopausal and Other Perimenopausal Disorders Age 40-52 History of regular menstrual cycles every 20-35 days in mid-reproductive life (20-35 years of age) At least 1 period within the past 3 months BMI less than 35 kg/m2 Presence of at least one of the following perimenopausal symptoms Hot flashes (vasomotor symptoms) Cyclical headache, bloating or adverse mood Self-reported poor quality of sleep  Age < 40 years Hysterectomy or bilateral oophorectomy Cigarette smoking Signs or symptoms of restless leg syndrome or sleep apnea Any chronic renal or hepatic disease that might interfere with excretion of gonadotropins or sex steroids Moderate/vigorous aerobic exercise > 4 hours per week Inability to read/write English Pregnant Women Prisoners Decisionally challenged subjects


eligible ages (years): 18.0-75.0,  All  Obstructive Sleep Apnoea males and females, age >18years and <75years, body-mass index (BMI) >18 and <40kg/m2, non-smokers, sleep apnoea with an ODI ≥15/h or sleep apnoea with an ODI ≥5/h plus an Epworth sleepiness score >10  morbid obesity (BMI>40kg/m2) or cachexia (BMI<18kg/m2), obesity-hypoventilation syndrome (total sleep time with SpO2<90% of more than 10% of the night), active smokers or smoking history of >20pack years, acute or critical illness, acute psychosis or chronic mental disorder affecting capacity, previous home-mechanical non-invasive ventilation and metal implants in the upper part of the body (this excludes dental implants)


eligible ages (years): 18.0-90.0,  All  Sleep Apnoea Syndrome patients with supected sleep apnoea syndrome and scheduled diagnosis at a sleep laboratory male and female patients aged at least 18 years persons who understand and follow the instructions of the study staff singed informed consent  persons being housed in an institution by court or governmental order pregnancy or breastfeeding patients who are not able to consent acute or chronic inflammations of the external and middle auditory canal abnormal anatomic proportionsof the external and middle auditory canal which are pathological or congenital, for example limitation of the auditory canal persons in a dependence or in an employment contract to the investigator participation in another study at the same time


eligible ages (years): 18.0-75.0,  All  Obstructive Sleep Apnea Syndrome Patients with low or medium suspicion of Sleep Apnea Patients with notorious comorbidity Age between 18 and 75 years Capability to fill in written questionnaires  Patients with high suspicion of sleep apnea Serious heart disease, resistant systemic hypertension, Suspicion of non-apneic sleep disorders, such as narcolepsy, REM behavior disorders and restless leg syndrome Patients with diagnosis of SAHS Lack of informed consent


eligible ages (years): 18.0-65.0,  All  Obstructive Sleep Apnoea (OSA) BMI > 35 attending bariatric surgery  retrognathia micrognathia acromegaly downs syndrome


eligible ages (years): 20.0-85.0,  All  Obstructive Sleep Apnea Central Sleep Apnea Mixed Sleep Apnea Cheyne-Stokes Respiration Able to understand and sign the informed consent Able to comply with visits and follow ups included in this protocol Ages 20-85 years  An unstable medical condition, acute or chronic, that in the opinion of the investigator puts the subject at health risks related this trial or interferes with the clinical trial and data collection Skin rash on the nose or on the maxillary area A history of skin allergy to medical tape, and hypoallergenic tapes A history of skin cancer on the nose or on the maxillary area A history of the base of skull fractures, facial fractures


eligible ages (years): 6.0-18.0,  All  Snoring Ability to understand how to perform reaction time test and complete without assistance  Children who are unable to understand or perform test or parents refusal


eligible ages (years): 18.0-999.0,  All  Obstructive Sleep Apnea End Stage Renal Disease end stage renal disease on renal replacement therapy age ≥ 18 years  unstable congestive heart failure active psychiatric disease


eligible ages (years): 2.5-5.917,  All  Sleep Initiation and Maintenance Disorders Age 30-71 months Child behavioral sleep problem, as demonstrated by a score on the Children's Sleep Habits Questionnaire (CSHQ) of at least 50, or a score of 41-49 and reported weeknight sleep of 9hrs or less per night English speaking parent or guardian  Sleep disordered breathing, as demonstrated by a score on the CSHQ of at least 5 Currently taking prescribed sleep medications, psychostimulants, and/or systemic corticosteroids Serious medical conditions likely to affect sleep, including diabetes or cancer Major cognitive or developmental disorder, including autism spectrum disorder


eligible ages (years): 16.0-999.0,  All  Acromegaly Adults aged 16 and above Referred to the Sleep Apnoea Clinic for assessment of obstructive sleep apnoea Have capacity to given informed consent  Patients under 16 years of age Not referred to the Sleep Apnoea Clinic Unable to give informed consent


eligible ages (years): 18.0-35.0,  All  PCOS Sleep Apnea Females 18 years old Receiving care at University of South Florida Reproductive Endocrinology Offices Polycystic ovarian syndrome defined by the modified Rotterdam Able to speak and understand as well as give informed consent in English  Late onset congenital adrenal hyperplasia Cushings disease Androgen-secreting tumors Previous diagnosis of obstructive sleep apnea Current use of over the counter or prescribed sleep medications Examples of medications that a patient from this study but are not limited to Unisom, Ambien or Lunesta Patients who are taking non-prescribed herbal medications for sleep will not be excluded from the study. Examples of these but are not limited to melatonin, chamomile, or valerian Untreated thyroid disease Prolactin excess Patients with the following medical conditions will be excluded from the study as portable sleep apnea monitors are not indicated in patients with severe pulmonary disease, neuromuscular disease, or congestive heart failure


eligible ages (years): 3.0-12.0,  All  Obstructive Sleep Apnea Syndrome Children aged 3-12 yrs, who are referred for clinical evaluation of habitual snoring and who were scheduled for an overnight polysomnogram  Children who are suffered from any chronic medical or psychiatric condition Children with acute respiratory infection Children with severe craniofacial deformities Children with cardiopulmonary diseases Children with a genetic syndrome that was known to affect cognitive abilities, or are receiving medications that are known to interfere with memory or sleep onset or heat rate


eligible ages (years): 18.0-18.0,  All  Sleep Apnea Sudden Cardiac Death Heart Failure Ischemic Cardiomyopathy Patients with ICM indicated for ICD/CRT-D implant based on current ESC Guidelines for primary prevention of sudden cardiac death  Previously diagnosed sleep apnea CPAP, BiPAP or ASV treatment Patients with previously implanted ICD/CRT-D device indicated for device replacement Uncontrolled hypertension Severe valvular heart disease/dysfunction with exception of ischemic and functional mitral regurgitation Acute coronary syndrome or acute cardiac decompensation in 4 weeks before ICD/CRT-D implant Expected indication of heart transplant in period of 12 months or less after ICD/CRT-D implant Expected cardiac surgery or percutaneous coronary intervention in period of 12 months or less after ICD/CRT-D implant Severe pulmonary diseases Rejection of participation in the study Pregnancy


eligible ages (years): 18.0-999.0,  All  Sleep Apnea Syndrome Men and Women over 18 years old Diagnosed as OSA and requiring CPAP treatment Written informed consent form signed  Patients with impaired lung function (overlap syndrome, obesity hypoventilation syndrome, and restrictive disorders) Severe heart failure Severe chronic pathology associated Psychiatric disorder Periodic leg movements Pregnancy Other dyssomnias or parasomnias Patients already treated with CPAP


eligible ages (years): 18.0-90.0,  All  Obstructive Sleep Apnoea Obesity Hypoxia men with or without obstructive sleep apnoea  weight loss interventions steroid use active smoking


eligible ages (years): 3.0-10.0,  All  Sleep-Disordered Breathing Diagnosis of mild sleep-disordered breathing (MSDB) defined by an obstructive apnea index (OAI) <1/hr and an apnea-hypopnea index (AHI) <2/hr confirmed by nocturnal polysomnography Parental report of habitual snoring defined as occurring on average >3 nights per week Tonsillar hypertrophy ≥2+ Deemed to be a surgical candidate for adenotonsillectomy by otolaryngologist evaluation  Previous tonsillectomy Recurrent tonsillitis that merits prompt adenotonsillectomy (AT) per the American Academy of Otolaryngology-Head and Neck Surgery Clinical Practice Guidelines (i.e., ≥7 episodes/yr in the past year; ≥5 episodes/year over the past 2 years or ≥3 episodes/yr over the past 3 years.) Severe obesity (body mass index (BMI) z-score ≥3) Severe chronic health conditions that might hamper participation or confound key variables under study Current use of psychotropic medication (other than medications for attention deficit hyperactivity disorder(ADHD)), hypnotics, antihypertensives or growth hormone History of severe developmental disability or Adaptive Behavior Assessment System (ABAS) score <60 Parent/guardian unable to accompany the children on the night of polysomnography (PSG) Family planning to move out of the area within the year Family does not speak English


eligible ages (years): 18.0-999.0,  All  Sleep Apnea/Hypopnea Syndrome Age 18 years or older No previous diagnosis of sleep apnea Fulfilling at least one of the following Pacemaker indication ICD or CRTD therapy indication Heart failure and preserved LVEF (40-50%) Heart failure and reduced LVEF (<40%) Signed informed consent  Age younger than 18 years Renal hemodialysis Cardiac transplant indication Women who are pregnant Advanced cancer Enrollment in another investigational study Able and willing to comply with all testing and requirements Patient not suitable for due to psychiatric conditions or short life expectancy


A 10 year old child is brought to the emergency room complaining of myalgia, cough, and shortness of breath.  Two weeks ago the patient was seen by his pediatrician for low-grade fever, abdominal pain, and diarrhea, diagnosed with a viral illness, and prescribed OTC medications. Three weeks ago the family returned home after a stay with relatives on a farm that raises domestic pigs for consumption. Vital signs: T: 39.5 C, BP: 90/60 HR: 120/min RR: 40/min. Physical exam findings include cyanosis,  slight stiffness of the neck,  and  marked periorbital edema. Lab results include WBC 25,000, with 25% Eosinophils, and an unremarkable urinalysis.

eligible ages (years): 18.0-999.0,  All  Cysticercosis Cysts Seizures years of age or older. If children are evaluated they can be seen under the general protocol and they may be entered into the present protocol under an exception Likely diagnosis of inactive cysticercosis and present or past seizure activity. Requires "a" and "b" plus any one of the remaining History of seizures or present seizure activity Previously treated or has inactive disease and declines treatment Single calcified lesions and positive serology Multiple calcified lesions Multiple small enhancing nodular lesions History of cystic lesions responding to specific chemotherapy If female, not pregnant and using effective birth control methods  Less than 18 years of age Pregnant or unwilling to use effective birth control measures Refuse blood tests Unwilling or unable to undergo testing according to the schedule Unable to undergo MRI or CT examinations Patients who require anesthesia to undergo imaging studies


eligible ages (years): 0.0-999.0,  All  Lung Diseases, Obstructive Chronic Obstructive Pulmonary Disease


eligible ages (years): 50.0-80.0,  All  Osteoporosis 80 years of age, inclusive years since last menses Dx femoral neck osteoporosis No vertebral fractures  Poor candidate for study drugs Hx of diseases affecting bone metabolism Hx of breast/estrogen-dependent cancer Current use of osteoporosis drug therapy Hx/high risk of VTE


eligible ages (years): 18.0-999.0,  All  Small Cell Lung Cancer Written informed consent (patient's written understanding of and agreement to participate in this study) Patients with confirmed extensive small cell lung cancer (SCLC) No prior chemotherapy within 5 years of the diagnosis of SCLC Presence of either measurable or non-measurable SCLC by X-ray or physical examination At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the patient) At least 24 hours since prior radiotherapy. Patients who have received radiotherapy must have recovered from any reversible side effects, such as nausea and vomiting Laboratory Patients must have adequate bone marrow reserve and adequate kidney and liver function  Symptoms of spreading of the disease to the brain that requires treatment with drugs called steroids Any active infection Severe medical problems other than the diagnosis of SCLC, that would limit the ability of the patient to follow study guidelines or that would expose the patient to extreme risk Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of SCLC Use of an investigational drug within 30 days before the first dose of study medication Women who are pregnant or lactating Patients of child-bearing potential who refuse to practice an adequate form of birth control Patients with clinical evidence of any stomach or intestinal (GI) condition Patients requiring treatment with the drug cyclosporin A


eligible ages (years): 18.0-999.0,  All  Sepsis Adult patients with severe sepsis Presence of a suspected or proven infection One or more sepsis-associated organ failure  Are indicated for the treatment with drotrecogin alfa (activated) in the investigative site country Are contraindicated for treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country Platelet count <30,000/mm3 Are receiving therapeutic heparin


eligible ages (years): 0.0-999.0,  All  Severe Acute Respiratory Syndrome Healthy adults, children and cord blood


eligible ages (years): 18.0-999.0,  All  Colon Mucinous Adenocarcinoma Colon Signet Ring Cell Adenocarcinoma Lynch Syndrome Stage IIA Colon Cancer Stage IIB Colon Cancer Stage IIC Colon Cancer STEP 1 The distal extent of the tumor must be >= 12 cm from the anal verge on endoscopy; if this distance was not confirmed on endoscopy pre-operatively, then the distal extent of the tumor must be >= 12 cm from the anal verge as determined by surgical examination; colonoscopy should be performed postoperatively for those unable to have a preoperative colonoscopy to guarantee there are no synchronous lesions; (if tumor is located beyond sigmoid colon and centimeter distance unavailable, anatomic region of colon, e.g. right colon, transverse colon, hepatic flexure descending colon, cecum etc.) Patients must have paraffin-embedded tumor specimen available for evaluation of microsatellite instability and loss of heterozygosity at 18q, to determine high risk versus low risk High-risk patients will be randomized to treatment Arms A or B Low-risk patients will be registered to Arm C for observation NOTE: Every effort should be made to submit blocks (tumor and normal mucosa) to the Principal Coordinates Analysis (PCO) immediately; blocks be accepted after day 50 (post surgery) in order to allow for molecular assessment Specific laboratory requirements for Step 2 must be obtained within 2 weeks prior to Step 2 randomization Patients must not have synchronous tumors Patients must not have appendiceal tumors Patients must not have a history of inflammatory bowel disease (IBD)


eligible ages (years): 8.0-17.0,  All  Asthma Allergy Children and adolescents between 8 and 17 years of age at the start of the trial (born after 01 March '88, but before 01 September '97) Bronchial asthma, diagnosed by a physician, and confirmed by a physician at a paediatric department of a Norwegian Hospital Allergy against dogs, confirmed by skin prick test. Average infiltrate at least 4 millimetres against dog, diagnosed by a new skin prick test at entry. For details about skin prick test, see attachment no. 6 Having had nose or breathing symptoms by contact with dogs, when no drugs against asthma or allergy have been taken Able to co-operate at cold air hyperventilation test and spirometry (see attachment no. 2) Given written consent (by parents of children below 12; by parents and child when above 12, but below 16; by patient when above 16)  Positive house dust mite skin prick test, with a more than 3 mm infiltrate Having taken oral beta-2-agonists or theophylline preparations for the last 2 weeks before trial start, or oral steroids for the last 3 months before start of the trial Active smoking Dogs or cats in the home Staying away from the home continuously for more than 14 days in the trial period or during the last month before trial start Being an in-patient in a special department or institution for asthma and allergy in the trial period or the last 3 months before the trial Having another chronic disease that can influence the results of ECP or cold air hyperreactivity tests Other types of mechanical ventilation or air filtration systems in the homes, except for those for kitchen stoves


eligible ages (years): 18.0-90.0,  All  Abscess Cysts Female or male, aged between 18 and 90 years Written informed consent Abscess formation or abdominal cyst scheduled to drainage Plasma creatinine <1.5 mg/dL  Pregnancy or lactation Hemodialysis or hemofiltration Allergy or hypersensitivity against study drugs Massive edemata or hypernatremia Reduced liver function (Child-Pugh A, B, C) Relevant prolongation of QT-interval CNS-diseases which predispose for cramps


eligible ages (years): 18.0-65.0,  All  West Nile Fever A participant must meet all of the following 18 to 65 years old Available for clinical follow-up through Week 32 and contact (correspondence, telephone or e-mail) or clinical visit through Week 52 of the study Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process Complete an Assessment of Understanding prior to enrollment and verbalize understanding of all questions answered incorrectly Able and willing to complete the informed consent process Willing to receive HIV test results and willing to abide by NIH guidelines for partner notification of positive HIV results Willing to donate blood for sample storage to be used for future research and genetic testing, including HLA analysis In good general health without clinically significant medical history and has satisfactorily completed screening Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) less than 40 within the 28 days prior to enrollment  A volunteer will be excluded if one or more of the following conditions apply Women Breast-feeding or planning to become pregnant during the 32 weeks of study participation Volunteer has received any of the following substances Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within the past six months. (Note that use of corticosteroid nasal spray for allergic rhinitis, topical corticosteroids for an acute uncomplicated dermatitis, or short-acting beta-agonists in controlled asthmatics are not excluded) Blood products within 120 days prior to HIV screening Immunoglobulin within 60 days prior to HIV screening Investigational research agents within 30 days prior to initial study vaccine administration Live attenuated vaccines within 30 days prior to initial study vaccine administration Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal, or allergy treatment with antigen injections, within 14 days of study vaccine administration


eligible ages (years): 18.0-50.0,  All  Ebola Hemorrhagic Fever Ebola Virus Disease Ebola Virus Vaccines Envelope Glycoprotein, Ebola Virus Filovirus A subject must meet all of the following 18 to 50 years old Available for clinical follow-up through Week 48 Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process Complete an AoU prior to enrollment and verbalize understanding of all questions answered incorrectly Able and willing to complete the informed consent process Willing to donate blood for sample storage to be used for future research In good general health without clinically significant medical history Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) less than 40 within the 28 days prior to enrollment Laboratory within 28 days prior to enrollment  A subject will be excluded if one or more of the following conditions apply Women Breast-feeding or planning to become pregnant during the first 24 weeks after enrollment Subject has received any of the following substances Ebola vaccines or any recombinant adenoviral vector vaccine in a prior clinical trial Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within the past six months. [Note: that use of corticosteroid nasal spray for allergic rhinitis, topical corticosteroids for an acute uncomplicated dermatitis, or short-acting beta-agonists in controlled asthmatics are not excluded.] Blood products within 120 days prior to HIV screening Immunoglobulin within 60 days prior to HIV screening Live attenuated vaccines within 30 days prior to initial study vaccine administration Investigational research agents within 30 days prior to initial study vaccine administration


eligible ages (years): 0.0-26.0,  All  Behavioral Disorders Being less than 26 years old Being pregnant for less than 27 weeks Being primiparous Living in the study area Being socially vulnerable: less than 12 years of education AND/OR socially isolated AND/OR eligible for a public health insurance for people with low resources  Refusal to participate Not able to speak French Having a medical follow-up which necessitates regular contact with health professional Not having health insurance Persons for whom follow up at 27 months is impossible (evaluation at baseline)


eligible ages (years): 0.0-999.0,  All  Influenza For pediatric population: Age of patient: 30 days years; for adult population: any age Illness onset within past 5 days Symptoms of fever (>=38°) plus one or more of the following: cough, runny nose, congestion, or sneezing (twice or more within one day). These symptoms must be present at the time of presentation to the emergency department (ED) or admission to the hospital Patient or parent/guardian is able to give informed consent  Pediatric patient or non-verbal adult is not accompanied by a caregiver Participant/caregiver cannot be reached by phone in 7-10 days Patient has a condition that can compromise respiratory function or the handling of respiratory secretions (e.g., severe cognitive dysfunction, spinal cord injuries, or other neuromuscular disorders)


eligible ages (years): 18.0-999.0,  All  Hypertension Obesity patients with essential hypertension aged >/= 18 years with one of the following risk factors: history of coronary artery disease or stroke/TIA or peripheral artery disease or diabetes mellitus  according to SPC


eligible ages (years): 18.0-999.0,  All  Scrub Typhus were Adults aged 18 years or older A fever of higher than 37.5°C The concurrent presence of eschar or a maculopapular skin rash; and the clear presence of more than two symptoms such as headache, malaise, myalgia, coughing, nausea and abdominal discomfort Patients were hospitalized at Chosun University Hospital in Kwangju, Korea or one of its two community-based affiliated hospitals which are all located in southwestern Korea between 2006 and 2009  The were An inability to take oral medications Pregnancy Hypersensitivity to the trial drugs Previous drug therapy with potential antirickettsial activity (e.g., rifampicin, chloramphenicol, macrolides, fluoroquinolones or tetracyclines) within 48 h prior to admission Severe scrub typhus (shock requiring vasopressor therapy for more than one hour A stuporous or comatose level of consciousness Respiratory failure requiring mechanical ventilation or renal failure requiring immediate dialysis) (4, 10) For the differential diagnosis of scrub typhus from other diseases with similar symptoms (e.g., murine typhus, leptospirosis, hemorrhagic fever with renal syndrome and systemic lupus erythematosus), patients underwent diagnostic tests. We thus excluded patients with concurrent infections who had the risk of causing different outcomes


eligible ages (years): 0.0-999.0,  All  Child Abuse resident of Durham, NC a child between the ages of 0-7 was the focus of the Department of Social Services report child's caregiver was the focus of the report Child Protective Services report occurred on or after June 1, 2004 family is English speaking Sexual abuse was not "confirmed" or "highly suspicious" during an evaluation  Child Protective Services report of sexual abuse that was "confirmed" or "highly suspicious"


eligible ages (years): 15.0-90.0,  All  Leptospirosis adult patients (> 14 years) with suspected severe leptospirosis patients who presented with acute fever (oral temperature more than 38.00 C for <15 days) in the absence of an obvious focus of infection In the opinion of the attending physician might have pulmonary hemorrhage (i.e. history of hemoptysis, and/ or bilateral nodular or air space infiltration)  pregnant or breastfeeding those with history of bleeding disorder those who had underlying diseases such as chronic liver disease, diabetes mellitus those who received diuretic or glucocorticoid


eligible ages (years): 18.0-45.0,  All  Familial Mediterranean Fever Fulfilling the Tel Hashomer for the diagnosis of FMF [5] Suffering from episodes of exertional leg pain and or exertional ankle edema 18-45 years old On a stable (≥ 2 weeks) dose of oral colchicine therapy Non-smokers  with known peripheral vascular disease (PVD) and/or multiple risk factors for PVD (such as diabetes, hypertension, hyperlipidemia) Suffering from muscular or neurological diseases not related to FMF With elevated serum creatinine / liver enzymes/ creatine phosphokinase (CPK) levels Suffering from claustrophobia, or with metal fragments in body tissue, or with other contraindications for MRI


eligible ages (years): 0.0-999.0,  All  Leishmaniasis DoD healthcare beneficiary of any age and gender Clinicoepidemiologic or parasitologic diagnosis (microscopy, PCR or culture) of Leishmania infection Able to provide informed consent or assent (children) All participants (both male and female) must agree to take precautions not to become pregnant or father a child for at least 2 months after receiving SSG  Pregnancy. Females of childbearing potential must have negative urine human chorionic gonadotropin hormone (HCG) within 96 hours start of infusion period History of hypersensitivity to pentavalent antimonials Any of the following on screening examination QTc interval greater or equal to 0.5 sec Severe cardiac disease (disabling valvular heart disease, myopathy, or arrhythmias) History of recurrent pancreatitis Liver failure or active hepatitis with transaminases > 3x upper limit of normal Renal failure or creatinine > 2.5 mg/dL Thrombocytopenia (platelets <100,000/mm3) White blood cell count < 2000 / mm3


eligible ages (years): 18.0-70.0,  All  Acute Viral Hepatitis Diabetes Mellitus All patients between the ages of 18 to 70 years  Recent intake of drugs known to cause acute hepatitis History of alcohol ingestion >40mg/day Suspected ischemic hepatitis Illness causing acute hepatitis such as Malaria hepatits, enteric hepatitis, Leptospirosis, septecemia HIV Associated co morbidities, which can affect survival such as cardiovascular disease and diabetic nephropathy Recent intake of drugs known to cause acute hepatitis History of alcohol ingestion >40mg/day Suspected ischemic hepatitis Malaria hepatits, enteric hepatitis, Leptospirosis, septecemia


eligible ages (years): 21.0-999.0,  All  Headache All patients who describe a painful sensation in the head as one of the primary reasons for their visit to the ED  patients who need immediate oxygen after triage: Recent fire or carbon monoxide exposure_______ O2 saturation 94% or less on room air on triage vitals ______ patient arrives on supplemental oxygen_______ patient reports shortness of breath_______ patients in whom 100% oxygen is contraindicated, potentially undesirable, or controversial: history of COPD_______ possible cardiac ischemia (mouth / jaw / neck / shoulder / chest / abdomen pain or pressure)_______ possible stroke (new focal weakness or numbness, speech, hearing or vision deficit, bowel or bladder incontinence or retention)_____ patients unable to tolerate the gas treatment: patient not able to tolerate a face mask_______ patient requests immediate treatment with another preferred therapeutic agent_______ treating physician or nurse request to discontinue the study at any point_______ patients who have diminished decision-making capacity history of mental retardation or pervasive developmental disorder_______ patient not awake and alert_______ patient not oriented to self, month and year, and current location_______ patient unwilling or unable to fully participate in the research associate interview and consent process_______ patients who are at risk for intracranial hemorrhage history of intracranial aneurythm, hemorrhage, surgery, or tumor_______ current headache began after trauma_______ current headache began after using elicit drugs_______ patients who are at high risk for intracranial infection fever > 100.4 F on triage vitals_______ complaining of recent onset neck stiffness_______ patients who are at high risk for extracranial head pathology ear pain or drainage_______ tooth or gum pain_______ headache localized to a skin lesion on the head______ patient is potentially critically ill active bleeding from any source_______ heart rate <60 or >130 on triage vitals_______ systolic blood pressure <90 or >180 on triage vitals_______ respiratory rate < 10 or >30 on triage vitals_______ patient is younger than 21_______


eligible ages (years): 18.0-999.0,  All  Recurrent Large Cell Lung Carcinoma Recurrent Lung Adenocarcinoma Recurrent Squamous Cell Lung Carcinoma Stage IV Large Cell Lung Carcinoma Stage IV Lung Adenocarcinoma Stage IV Squamous Cell Lung Carcinoma Patients must have histologically or cytologically proven primary non-small cell lung cancer (adenocarcinoma, large cell carcinoma, squamous or unspecified); disease must be stage IV; disease may be either newly diagnosed or recurrent after previous surgery and/or irradiation; patients with additional lesions in an ipsilateral non-primary lobe without M1a or M1b disease will not be considered to have stage IV disease and are not eligible Patients must have a computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to registration; patient must not have brain metastases unless: (1) metastases have been treated and have remained controlled for at least two weeks following treatment, AND (2) patient has no residual neurological dysfunction off corticosteroids for at least 1 day Patients may have measurable or non-measurable disease documented by CT or MRI; the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form Patients must have tumor tissue available for submission that is sufficient for EGFR FISH testing and must agree to submission of these specimens; patients must also agree to submission of specimens for other translational medicine studies; patient must be offered participation in banking for future research Patients must not have received prior chemotherapy for any stage non-small cell lung cancer; patients must not have received prior platinum-based chemotherapy for any purpose; patient must not have received any cetuximab, gefitinib, erlotinib, or other investigational agents that target the EGFR pathway; patients must not have received for any purpose prior bevacizumab or other vascular endothelial growth factor (VEGF)-related agents; patients must not have received for any purpose prior chimerized or murine monoclonal antibody therapy or have documented presence of human anti-mouse antibodies (HAMA) Prior radiation is permitted; however, patients must have recovered from all associated toxicities at time of registration; in order to qualify as measurable, measurable disease must be outside the previous radiation field or must have progressed Time from surgical or biopsy procedures is dependent on whether it is planned for the patient to receive bevacizumab For patients who are bevacizumab-appropriate AND bevacizumab is planned: at least 28 days must have elapsed since major surgery (i.e. thoracotomy or video-assisted thoracoscopic surgery [VATS] resection of lung cancer, open pleural biopsy or another major surgical procedure such as abdominal surgery) or significant traumatic injury; patients must have recovered from all associated toxicities at the time of registration; there must be no anticipation of need for major surgical procedures during protocol treatment; patients must not have had a core biopsy, mediastinoscopy, pleurodesis, VATS pleural biopsy or VATS pericardial window within 14 days prior to registration; patients must not have had a percutaneous fine needle aspiration (FNA), thoracentesis or central venous access device implanted within 7 days prior to registration; for other surgical procedures not listed here, please contact the study coordinators For patients who are bevacizumab-inappropriate or bevacizumab is not planned: at least 28 days must have elapsed since major surgery (i.e. thoracotomy or VATS resection of lung cancer, open pleural biopsy or another major surgical procedure such as abdominal surgery) or significant traumatic injury; patients must have recovered from all associated toxicities at the time of registration; there must be no anticipation of need for major surgical procedures during protocol treatment; patients must not have had a core biopsy, mediastinoscopy, pleurodesis, VATS pleural biopsy or VATS pericardial window within 7 days prior to registration; patients must not have had a percutaneous fine needle aspiration (FNA), or thoracentesis within 1 day prior to registration; patients may have had a central venous access device placed at any time prior to registration; for other surgical procedures not listed here, please contact the study coordinators Absolute neutrophil count (ANC) >= 1,500/mcl


eligible ages (years): 17.0-65.0,  All  Crimean-Congo Hemorrhagic Fever Lassa Fever An individual will be enrolled in this study if the patient Meets the case definition for a probable or a suspected case of CCHF or LF (see below) Has read and signed the Informed Consent Is at least 18 years of age (17, if active military) and not greater than 65 years of age Has a blood sample drawn and a type and cross-match ordered for transfusion Agrees to collection of required specimens Agrees to report any Adverse Events, Serious and Unexpected Adverse Events for the duration of the study Agrees to a follow-up visit and to donate blood and urine specimens at day 14 (±2 days) and once between days 28 and 60 after the first dose of IV Ribavirin and to all follow-up visits for anemia or other medical conditions as required by the attending physician Woman of childbearing age must have a pregnancy test performed. If negative, she must agree not to become pregnant during treatment and for 7 months after receiving Ribavirin. She also must agree to not breast feed during treatment and for 7 months after receiving Ribavirin. Two reliable forms of effective contraception must be used including one barrier method during treatment and during the 7 month post-treatment period. She will be counseled concerning the risks of IV Ribavirin versus no treatment if the pregnancy test is positive Man agrees not to have intercourse with pregnant woman during treatment and for 7 months after receiving Ribavirin, and take precautions to avoid producing pregnancies during treatment and for 7 months after receiving Ribavirin. At least two reliable forms of effective contraception must be used including one barrier method during treatment and during the 7 month post-treatment period to avoid a pregnancy  Has known intolerance to Ribavirin Is irreversibly ill on presentation, as defined by presence of profound shock (shock which does not respond to supportive therapy within 3 hours after admission) Has hemoglobin less than 10 g/dL that cannot be corrected to 10 g/dL before initiation of IV Ribavirin Has history of hemoglobinopathies (i.e., sickle-cell anemia or thalassemia major) Has history of autoimmune hepatitis Has a calculated serum creatinine clearance of < 30 mL/min History of such as second or third degree heart block or sick sinus syndrome and without a pacemaker and no capability of a pacemaker placement or Wolfe-Parkinson-White Syndrome A sinus bradycardia of less than 40 beats per minute Is currently being treated with Didanosine (ddI). ddI must be discontinued before starting IV Ribavirin Relative


eligible ages (years): 18.0-80.0,  All  Septic Shock Sepsis all patients aged between 18 and 80 years old with the diagnostic of septic shock or severe sepsis  pregnants previous diagnosis of any cancer diagnosis of leptospirosis diagnosis of aids


eligible ages (years): 0.0-999.0,  All  Flavivirus Infection Alphavirus Infections Malaria Parasitic Disease Leptospirosis Hypertension Metabolic Syndromes For community participants: Health volunteers who are willing to join this study (including the stool and blood testing) after explanation and sign the informed consents For hospital cases: The patients ,who were suspicious of malaria, leptospirosis, Alpha-viral(Chikungunya virus, Ross river virus), and flavivirus infections (dengue fever, Japanese encephalitis..ect) by the attending physicians, will be informed about this study by drawing blood samples if they agree to participate  The participants whose stool or blood samples were in-adequate or missing will be excluded from this study The participants whose documented personal information is fake or cannot be identifiable will also be excluded from this study


eligible ages (years): 18.0-999.0,  All  Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection Age > 18 years Transplanted by a functional kidney affected by a hepatitis E chronic Benefiting from a follow-up in the Center of Nephrology and renal Transplantation or in the service of Hépato-gastro-entérologie of the CHU The Conception in Marseille Having signed a consent informed about participation in the study  Affected by another sharp or chronic viral infection


eligible ages (years): 18.0-85.0,  All  Japanese Encephalitis Living in the specific 2 villages in Hualien county Aged 18-85  Difficulty to have blood test due to coagulopathy or small blood vessels


eligible ages (years): 0.0-999.0,  All  QIAGEN ResPlex II Advanced Panel Influenza A Influenza B Respiratory Syncytial Virus Infections Infection Due to Human Parainfluenza Virus 1 Parainfluenza Type 2 Parainfluenza Type 3 Parainfluenza Type 4 Human Metapneumovirus A/B Rhinovirus Coxsackie Virus/Echovirus Adenovirus Types B/C/E Coronavirus Subtypes 229E Coronavirus Subtype NL63 Coronavirus Subtype OC43 Coronavirus Subtype HKU1 Human Bocavirus Artus Influenza A/B RT-PCR Test Influenza A, Influenza B, Subjects that sign the Informed Consent form required for prospectively enrolling patients into the study Subjects that present at a hospital, clinic, or physician's office with the signs and symptoms of a respiratory tract infection Subjects with an acute respiratory infection where said acute respiratory infection is suspected of being caused by an Influenza virus  Subjects where the duration of the symptoms of such an acute respiratory infection is greater than or equal to 5 days (i.e., ≥5)


eligible ages (years): 40.0-80.0,  All  Pulmonary Disease, Chronic Obstructive Type of subject: outpatient Informed consent: Subjects must give their signed and dated written informed consent to participate Gender: Male or female. Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to or women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception Age: >=40 and <=80 years of age at Screening (Visit 1) Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at screening (Visit 1). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1 Airflow Obstruction Subjects with a measured post-albuterol/salbutamol forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio of <=0.70 at Screening (Visit 1) Subjects with a measured post-albuterol/salbutamol FEV1 >=50 and <=70% of predicted normal values calculated using III reference equations [Hankinson, 1999; Hankinson, 2010] at Screening (Visit 1) Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated Symptoms of COPD: Subjects must score 2 or higher on the modified Medical Research Council Dyspnea scale (Visit 1)  Pregnancy: Women who are pregnant or lactating Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they also have a current diagnosis of COPD) alpha 1-antitrypsin deficiency: Subjects with known alpha-1 antitrypsin deficiency as the underlying cause of COPD Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases Lung resection or transplantation: Subjects with lung volume reduction surgery within the 12 months prior to Screening or having had a lung transplant A moderate/severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable) Current severe heart failure (New York Heart Association class IV). Subjects will also be excluded if they have a known ejection fraction of <30% or if they have an implantable cardioverter defibrillator (ICD) Other diseases/abnormalities: Any life-threatening condition with life expectancy <3 years, other than vascular disease or COPD, that might prevent the subject from completing the study End stage chronic renal disease: Subjects will be excluded if on renal replacement therapy (hemodialysis or peritoneal) Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate). In addition, patients with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded


eligible ages (years): 0.5-100.0,  All  Staphylococcus Aureus Infection Cohort A: Participant or child of participant in the Agricultural Health Study Cohort B: Resident of Iowa  Cohort A: Age < 8 months Cohort B: Age < 8 months


eligible ages (years): 4.0-18.0,  All  Ascaris Lumbricoides Ascaris Suum Trichuris Trichiura Trichuris Vulpis Ancylostoma Duodenal Ancylostoma Caninum Ancylostoma Ceylanicum Necator Americanus   Subjects who are unable to provide a stool sample at follow-up Subjects who are experiencing a severe concurrent medical condition Subjects with diarrhea at first sampling


eligible ages (years): 0.0-999.0,  All  Cough Myalgia Nasal Obstruction Sore Throat Headache Fatigue Fever Those who exhibit flu-like symptom(s) during a flu season and who (or whose guardians) are willing to participate in the study